The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Open accessPublished version of a preprint
Abstract
The CRISPR-Cas9 system is a powerful tool for genome editing, which allows the precise modification of specific DNA sequences. Many efforts are underway to use the CRISPR-Cas9 system to therapeutically correct human genetic diseases 1-6. The most widely used orthologs of Cas9 are derived from Staphylococcus aureus and Streptococcus pyogenes 5,7. Given that these two bacterial species infect the human population at high frequencies 8,9, we hypothesized that humans may harbor preexisting adaptive immune responses to the Cas9 orthologs derived from these bacterial species, SaCas9 (S. aureus) and SpCas9 (S. pyogenes). By probing human serum for the presence of anti-Cas9 antibodies using an enzyme-linked immunosorbent assay, we detected antibodies against both SaCas9 and SpCas9 in 78% and 58% of donors, respectively. We also found anti-SaCas9 T cells in 78% and anti-SpCas9 T cells in 67% of donors, which demonstrates a high prevalence of antigen-specific T cells against both orthologs. We confirmed that these T cells were Cas9-specific by demonstrating a Cas9-specific cytokine response following isolation, expansion, and antigen restimulation. Together, these data demonstrate that there are preexisting humoral and cell-mediated adaptive immune responses to Cas9 in humans, a finding that should be taken into account as the CRISPR-Cas9 system moves toward clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second, long-term expression of genome editing molecules may expose patients to undesired off-target editing or immune reactions 66,67 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-existing Cas9 antibodies and reactive T-cells have been detected in humans exposed to pathogenic bacteria harboring CRISPR systems, although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it is unknown whether these are present at concentrations sufficient to trigger an immune response to the genome editing enzymes 66,104 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other factors affecting clinical applications of genome editing include the immunogenicity of bacterially-derived editing proteins, the potential for pre-existing antibodies against CRISPR components to cause inflammation and the unknown long-term safety and stability of genome editing outcomes.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [66]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Another consideration for CRISPR/Cas9-based systems for retinal gene editing is the potential for a heightened adaptive immune response given the bacterial origin of the Cas9 enzyme and high prevalence of pre-existing immunity (Charlesworth et al., 2019).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Charlesworth et al., 2019
In the citing paper
“A study involving 125 healthy adult human blood donors in the USA with a median age of 43 reported pre-existing anti-SaCas9 antibodies and anti-SpCas9 antibodies in 78% and 58% of the total samples, respectively.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“Among the tested donors, 78% had SaCas9-specific T-cells and 67% were positive for SpCas9-specific T-cells.”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [24]
In the citing paper
“While there are discrepancies regarding the exact prevalence of these antibodies in humans, a majority of the general population may exhibit preexisting α-Cas93.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“Furthermore, a high prevalence of preexisting cellular immunity against Cas9 (Cas9-reactive T-cells) has also been identified2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“multiple groups have reported high frequencies (>60% of patients) of Cas9 reactive T-cells in humans2–4.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“This may explain the lower raw ELISA A450 values we observed compared with previous work (Table 1)3.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [3]
In the citing paper
“CRISPR-Cas9 is a promising therapeutic tool that allows genetic target-specific cleavage and editing (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
In the citing paper
“One concern is that the prevalence of anti-SaCas9 antibodies and T-cell in humans are reported to be 78% (111).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,018
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Pukelsheim, F. (1994) · The American Statistician · doi:10.1080/00031305.1994.10476030 · Cited by 1,072
Cited by
Sorted by citations
Items 201–300 of 1,000
Functional Features and Current Applications of the RNA‐Targeting Type VI CRISPR‐Cas Systems
Perčulija, V., Lin, J., Zhang, B., & Ouyang, S. (2021) · Advanced Science · doi:10.1002/advs.202004685 · Cited by 60
Site-directed RNA editing: recent advances and open challenges
Mansouri, H. R., & Jantsch, M. F. (2021) · RNA Biology · doi:10.1080/15476286.2021.1983288 · Cited by 61
An Update on the Application of CRISPR Technology in Clinical Practice
Morshedzadeh, F., Ghanei, M., Lotfi, M., Ghasemi, M., Ahmadi, M., Najari-Hanjani, P., Sharif, S., Mozaffari‐Jovin, S., Peymani, M., & Abbaszadegan, M. R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00724-z · Cited by 62
CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment
Bonowicz, K., Jerka, D., Piekarska, K., Olagbaju, J., Stapleton, L., Shobowale, M., Bartosiński, A., Łapot, M., Bai, Y., & Gagat, M. (2025) · Cells · doi:10.3390/cells14020131 · Cited by 62
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy
Guo, N., Liu, J., Li, W., Ma, Y., & Fu, D. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.018 · Cited by 64
Nanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 58
Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9
Stephens, C. J., Kashentseva, E. A., Everett, W., Kaliberova, L. N., & Curiel, D. T. (2018) · Gene Therapy · doi:10.1038/s41434-018-0003-1 · Cited by 57
Klompe, S. E., & Sternberg, S. H. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0012 · Cited by 57
Precision gene editing technology and applications in nephrology
WareJoncas, Z., Campbell, J. M., Martínez‐Gálvez, G., Gendron, W. A. C., Barry, M. A., Harris, P. C., Sussman, C. R., & Ekker, S. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0047-x · Cited by 61
Engineering designer beta cells with a CRISPR-Cas9 conjugation platform
Lim, D., Sreekanth, V., Cox, K. J., Law, B. K., Wagner, B. K., Karp, J. M., & Choudhary, A. (2020) · Nature Communications · doi:10.1038/s41467-020-17725-0 · Cited by 59
Nucleic Acid-Based Technologies Targeting Coronaviruses
Le, T. K., Paris, C., Khan, K. S., Robson, F., Ng, W., & Rocchi, P. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.11.010 · Cited by 57
CRISPR/Cas mediated epigenome editing for cancer therapy
Ansari, I., Chaturvedi, A., Chitkara, D., & Singh, S. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.018 · Cited by 58
Ou, X., Ma, Q., Yin, W., Ma, X., & He, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674467 · Cited by 58
Amini, L., Wagner, D. L., Rössler, U., Zarrinrad, G., Wagner, L. F., Vollmer, T., Wendering, D. J., Kornak, U., Volk, H., Reinke, P., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.011 · Cited by 56
Methods and applications of CRISPR/Cas system for genome editing in stem cells
Yang, G., & Huang, X. (2019) · Cell Regeneration · doi:10.1016/j.cr.2019.08.001 · Cited by 55
Targeted Therapy in Cardiovascular Disease: A Precision Therapy Era
Xu, M., Zhang, K., & Song, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623674 · Cited by 55
CRISPR technologies for the treatment of Duchenne muscular dystrophy
Choi, E., & Koo, T. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.002 · Cited by 57
Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells
Lotfi, M., Rad, D. M., Mashhadi, S., Ashouri, A., Mojarrad, M., Mozaffari‐Jovin, S., Farrokhi, S., Hashemi, M., Lotfi, M., Warkiani, M. E., et al. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10585-3 · Cited by 54
Efficient plant genome engineering using a probiotic sourced CRISPR-Cas9 system
Zhong, Z., Liu, G., Tang, Z., Xiang, S., Yang, L., Huang, L., He, Y., Fan, T., Liu, S., Zheng, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41802-9 · Cited by 58
Hsu, M., Yu, F.-J., Chang, Y., Huang, K.-L., Pham, N. N., Truong, V. A., Lin, M., Nguyen, N. T. K., Hwang, S., & Hu, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120094 · Cited by 54
Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors
Shalaby, K. E., Aouida, M., & El‐Agnaf, O. M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197353 · Cited by 55
Efficient viral delivery of Cas9 into human safe harbor
Hayashi, H., Kubo, Y., Izumida, M., & Matsuyama, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78450-8 · Cited by 54
A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing
Sinha, S., Barbosa, K., Cheng, K., Leiserson, M. D. M., Jain, P., Deshpande, A. J., Wilson, D. M., Ryan, B. M., Luo, J., Ronai, Z. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26788-6 · Cited by 56
CRISPR: History and perspectives to the future
Kozovská, Z., Rajcaniova, S., Munteanu, P., Dzacovska, S., & Demková, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111917 · Cited by 60
Ren, D., Fisson, S., Dalkara, D., & Ail, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091973 · Cited by 52
Rational engineering of minimally immunogenic nucleases for gene therapy
Raghavan, R. S., Friedrich, M., King, C., Vo, C.-D.-T., Strebinger, D., Lash, B., Kilian, M., Platten, M., Macrae, R. K., Song, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55522-1 · Cited by 56
CRISPR/Cas system: An emerging technology in stem cell research
Valenti, M. T., Serena, M., Carbonare, L. D., & Zipeto, D. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i11.937 · Cited by 54
CRISPR/Cas9-Mediated miR-29b Editing as a Treatment of Different Types of Muscle Atrophy in Mice
Li, J., Wang, L., Hua, X., Tang, H., Chen, R., Yang, T., Das, S., & Xiao, J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.005 · Cited by 54
Allemailem, K. S., Almatroodi, S. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Al‐Megrin, W. A. I., Aljamaan, A. N., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087052 · Cited by 53
Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy
Luo, Z., Huang, Y., Batra, N., Chen, Y., Huang, H., Wang, Y., Zhang, Z., Li, S., Chen, C., Wang, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44572-6 · Cited by 51
Activation of Necroptosis by Engineered Self Tumor-Derived Exosomes Loaded with CRISPR/Cas9
Gulei, D., & Berindan‐Neagoe, I. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.032 · Cited by 51
Progress of delivery methods for CRISPR-Cas9
Yang, W., Yan, J., Zhuang, P., Ding, T., Chen, Y., Zhang, Y., Zhang, H., & Cui, W. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2100342 · Cited by 52
Insights into the Mechanism of CRISPR/Cas9-Based Genome Editing from Molecular Dynamics Simulations
Bhattacharya, S., & Satpati, P. (2022) · ACS Omega · doi:10.1021/acsomega.2c05583 · Cited by 51
O’Geen, H., Beitnere, U., Garcia, M. S., Adhikari, A., Cameron, D. L., Fenton, T. A., Copping, N. A., Deng, P., Lock, S., Halmai, J. A. N. M., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.013 · Cited by 51
Control of mammalian gene expression by modulation of polyA signal cleavage at 5′ UTR
Luo, L., Jea, J. D.-Y., Wang, Y., Chao, P.-W., & Yen, L. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01989-0 · Cited by 50
Clinical applications of CRISPR‐based genome editing and diagnostics
Foss, D. V., Hochstrasser, M. L., & Wilson, R. C. (2019) · Transfusion · doi:10.1111/trf.15126 · Cited by 51
Lux, C. T., Pattabhi, S., Berger, M. P., Nourigat, C., Flowers, D. A., Nègre, O., Humbert, O., Yang, J., Lee, C., Jacoby, K., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.008 · Cited by 52
Xu, L. M., Lau, Y. S., Gao, Y., Bailin, P. L., & Han, R. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.001 · Cited by 51
Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
Pavani, G., Laurent, M., Fabiano, A., Cantelli, E., Sakkal, A., Corre, G., Lenting, P. J., Concordet, J., Toueille, M., Miccio, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17552-3 · Cited by 54
Gene Delivery to the Skin – How Far Have We Come?
Ain, Q. U., Campos, E. V. R., Huynh, A., Witzigmann, D., & Hedtrich, S. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.07.012 · Cited by 51
Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
Kim, D., Le, Q., Wu, Y., Park, J.-W., & Oh, Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121233 · Cited by 51
Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications
Bećirović, E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04175-8 · Cited by 52
Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs
Stahl, E. C., Sabo, J. K., Kang, M. H., Allen, R., Applegate, E., Kim, S., Kwon, Y., Seth, A., Lemus, N., Salinas-Rios, V., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.019 · Cited by 51
Recent Therapeutic Gene Editing Applications to Genetic Disorders
Deneault, É. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46050255 · Cited by 54
Strategies for the CRISPR-Based Therapeutics
Li, B., Niu, Y., Ji, W., & Dong, Y. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.006 · Cited by 52
Editing the Central Nervous System Through CRISPR/Cas9 Systems
Cota-Coronado, A., Díaz-Martínez, N. F., Padilla‐Camberos, E., & Diaz-Martinez, N. E. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00110 · Cited by 51
The Future of In Utero Gene Therapy
Peranteau, W. H., & Flake, A. W. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00445-y · Cited by 47
Leveraging a natural murine meiotic drive to suppress invasive populations
Gierus, L., Birand, A., Bunting, M. D., Godahewa, G., Piltz, S. G., Oh, K. P., Piaggio, A., Threadgill, D., Godwin, J., Edwards, O., et al. (2022) · bioRxiv · doi:10.1073/pnas.2213308119 · Cited by 43
Palacios, A. M., Korus, P., Wilkens, B. G. C., Heshmatpour, N., & Patnaik, S. R. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1342193 · Cited by 49
Synthesis of green benzamide-decorated UiO-66-NH2 for biomedical applications
Rabiee, N., Ghadiri, A. M., Alinezhad, V., Sedaghat, A., Ahmadi, S., Fatahi, Y., Makvandi, P., Saeb, M. R., Bagherzadeh, M., Asadnia, M., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.134359 · Cited by 46
CRISPR-Editing Therapy for Duchenne Muscular Dystrophy
Chemello, F., Olson, E. N., & Bassel‐Duby, R. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.053 · Cited by 47
Li, Z., Guo, R., Sun, X.-Z., Li, G., Shao, Z., Huo, X., Yang, R., Liu, X., Cao, X., Zhang, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45197-z · Cited by 46
Zhang, M., Li, H., & Jin, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1364742 · Cited by 49
Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 48
Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing
Hanson, B., Wood, M. J. A., & Roberts, T. C. (2021) · RNA Biology · doi:10.1080/15476286.2021.1874161 · Cited by 49
Ashraf, M. U., Salman, H. M., Khalid, M. F., Khan, M. H. F., Anwar, S., Afzal, S., Idrees, M., & Chaudhary, S. U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111239 · Cited by 48
Liver‐directed gene therapy for inherited metabolic diseases
Baruteau, J., Brunetti‐Pierri, N., & Gissen, P. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12709 · Cited by 46
Diagnostic, Therapeutic, and Theranostic Multifunctional Microneedles
Ertaş, Y. N., Ertas, D., Erdem, A., Segujja, F., Dulchavsky, S. A., & Ashammakhi, N. A. (2024) · Small · doi:10.1002/smll.202308479 · Cited by 45
Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety
Teboul, L., Hérault, Y., Wells, S. E., Qasim, W., & Pavlovic, G. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.015 · Cited by 47
Programmable RNA base editing via targeted modifications
Song, J., Zhuang, Y., & Yi, C. (2024) · Nature Chemical Biology · doi:10.1038/s41589-023-01531-y · Cited by 44
Sun, R., Qian, M. G., & Zhang, X. (2024) · mAbs · doi:10.1080/19420862.2024.2324836 · Cited by 46
Uzakova, A., Yergaliyeva, E. M., Yerlanuly, A., & Mukatayeva, Z. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics18010011 · Cited by 45
Weissman, J., Laljani, R. M. R., Fagan, W. F., & Johnson, P. L. F. (2019) · The ISME Journal · doi:10.1038/s41396-019-0411-2 · Cited by 44
Exploring the methyl-verse: Dynamic interplay of epigenome and m6A epitranscriptome
Pilala, K., Panoutsopoulou, K., Papadimitriou, M., Soureas, K., Scorilas, A., & Avgeris, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.003 · Cited by 43
Personalised genome editing – The future for corneal dystrophies
Moore, T., Christie, K. A., Marshall, J., & Nesbit, M. A. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.01.004 · Cited by 44
Valeur, E., & Jimonet, P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00378 · Cited by 43
CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities
Raaijmakers, R. H. L., Ripken, L., Ausems, C. R. M., & Wansink, D. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153689 · Cited by 46
Genome Editing for Mucopolysaccharidoses
Poletto, É., Baldo, G., & Gomez‐Ospina, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020500 · Cited by 45
Self-citationTranslating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 43
Jubair, L., Lam, A. K.-Y., Fallaha, S., & McMillan, N. A. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0223288 · Cited by 43
Gardner, C. L., Pavel-Dinu, M., Dobbs, K., Bosticardo, M., Reardon, P. K., Lack, J., Ravin, S. S. D., Le, K., Bello, E. A., Pala, F., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-00989-6 · Cited by 43
Self-citationPreclinical safety and biodistribution of CRISPR targeting SIV in non-human primates
Burdo, T. H., Chen, C., Kaminski, R., Sariyer, I. K., Mancuso, P., Donadoni, M., Smith, M. D., Sariyer, R., Caocci, M., Liao, S., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00410-4 · Cited by 42
Novel therapeutic strategies for chronic hepatitis B
Phillips, S., Jagatia, R., & Chokshi, S. (2022) · Virulence · doi:10.1080/21505594.2022.2093444 · Cited by 44
Genome-editing strategies for treating human retinal degenerations
Quinn, J., Musa, A., Kantor, A., McClements, M. E., Cehajic-Kapetanovic, J., MacLaren, R. E., & Xue, K. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.231 · Cited by 41
Paving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 43
Cheng, Y., Wang, H., & Li, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108524 · Cited by 45
CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics
Tiwari, P. K., Ko, T.-H., Dubey, R., Chouhan, M., Tsai, L.-W., Singh, H. N., Chaubey, K. K., Dayal, D., Chiang, C., & Kumar, S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1214489 · Cited by 42
Therapeutic genome editing in cardiovascular diseases
Nishiga, M., Qi, L. S., & Wu, J. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.003 · Cited by 42
Immunity to Cas9 as an Obstacle to Persistent Genome Editing
Gough, V., & Gersbach, C. A. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.007 · Cited by 41
Lessons learned from lung and liver in-vivo gene therapy: implications for the future
van Haasteren, J., Hyde, S. C., & Gill, D. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1506761 · Cited by 43
CRISPR to fix bad blood: a new tool in basic and clinical hematology
González-Romero, E., Martínez-Valiente, C., García-Ruiz, C., Vázquez‐Manrique, R. P., Cervera, J., & Sanjuán-Pla, A. (2019) · Haematologica · doi:10.3324/haematol.2018.211359 · Cited by 42
A more efficient CRISPR-Cas12a variant derived from Lachnospiraceae bacterium MA2020
Tran, M. H., Park, H., Nobles, C. L., Karunadharma, P. P., Pan, L., Zhong, G., Wang, H., He, W., Ou, T., Crynen, G. C., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.02.012 · Cited by 41
The Application of CRISPR/Cas Systems for Antiviral Therapy
Baddeley, H. J. E., & Isalan, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.745559 · Cited by 41
He, X., Zhang, Z., Xue, J., Wang, Y., Zhang, S., Wei, J., Zhang, C., Wang, J., Urip, B. A., Ngan, C. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34898-y · Cited by 43
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.009 · Cited by 40
Programmable RNA base editing with a single gRNA-free enzyme
Han, W., Huang, W., Wei, T., Ye, Y., Mao, M., & Wang, Z. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac713 · Cited by 39
Yi, Z., Zhao, Y., Yi, Z., Zhang, Y., Tang, G.-B., Zhang, X., Tang, H., Zhang, W., Zhao, Y., Xu, H., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03086-6 · Cited by 41
Therapeutic gene editing in haematological disorders with CRISPR /Cas9
Jensen, T. I., Axelgaard, E., & Bak, R. O. (2019) · British Journal of Haematology · doi:10.1111/bjh.15851 · Cited by 40
Emerging gene therapies for cystic fibrosis
Miah, K. M., Hyde, S. C., & Gill, D. R. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1634547 · Cited by 39
Hematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies
Drysdale, C. M., Nassehi, T., Gamer, J., Yapundich, M., Tisdale, J. F., & Uchida, N. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.001 · Cited by 39
Lee, B., Lozano, R. J., & Dunbar, C. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.001 · Cited by 39
Chen, Z., Kelly, K., Cheng, H., Dong, X., Hedger, A. K., Li, L., Sontheimer, E. J., & Watts, J. K. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0045 · Cited by 37
CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing
Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.013 · Cited by 38
Nanoparticle delivery systems for substance use disorder
Kasina, V., Mownn, R. J., Bahal, R., & Sartor, G. C. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01311-7 · Cited by 39
Loo, L., Harris, S., Milton, M., Meena, M., Lembke, W., Berisha, F., Bertholet, S., Dessy, F. J., Dodge, R. W., Fang, X., et al. (2022) · Bioanalysis · doi:10.4155/bio-2022-0081 · Cited by 37
Self-citationAdvances in CRISPR Delivery Methods: Perspectives and Challenges
Demirci, S., Essawi, K., Germino-Watnick, P., Liu, X., Hakami, W., & Tisdale, J. F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0051 · Cited by 37
Genome Editing, A Superior Therapy for Inherited Retinal Diseases
Yan, A. L., Du, S. W., & Palczewski, K. (2022) · Vision Research · doi:10.1016/j.visres.2023.108192 · Cited by 37
CRISPR-assisted transcription activation by phase-separation proteins
Liu, J., Chen, Y., Nong, B., Luo, X., Cui, K., Li, Z., Zhang, P., Tan, W., Yang, Y., Ma, W., et al. (2023) · Protein & Cell · doi:10.1093/procel/pwad013 · Cited by 37
Metadata
- Authors
- Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., Behlke, M. A., Dejene, B., Cieniewicz, B., Romano, R., Lesch, B. J., Gomez-Ospina, N., Mantri, S., Pavel-Dinu, M., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford Medicine (US)
- Integrated DNA Technologies (United States) (US)
- Corresponding author
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- ORCID
- Charlesworth, Carsten T.
- Dever, Daniel P.
- Camarena, Joab
- Lemgart, Viktor T.
- Cromer, M. Kyle
- Vakulskas, Christopher A.
- Collingwood, Michael A.
- Zhang, Liyang
- Bode, Nicole M.
- Behlke, Mark A.
- Dejene, Beruh
- Cieniewicz, Brandon
- Romano, Rosa
- Lesch, Benjamin J.
- Gomez-Ospina, Natalia
- Mantri, Sruthi
- Pavel-Dinu, Mara
- Weinberg, Kenneth I.
- Porteus, Matthew H.
- Venue
- Nature Medicine
- Published
- 2019-01-28
- Volume
- 25
- Issue
- 2
- Pages
- 249-254
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7199589
- OpenAlex
- W2949380898
- Cited by
- 1,093
- References
- 48
- Citations by year
- 2026: 130 · 2025: 128 · 2024: 132 · 2023: 111 · 2022: 125 · 2021: 166 · 2020: 131 · 2019: 110
- FWCI
- 44.16
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nd)
- Funders
- Amon G. Carter Foundation
- National Institutes of Health (5r01ai120766-02)
- National Institute of General Medical Sciences (T32GM119995)
- National Institute of Allergy and Infectious Diseases (R01-AI120766)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, SaCas9, SpCas9, Staphylococcus aureus, Streptococcus pyogenes, humoral immune response, cell-mediated immunity, genome editing safety
- MeSH terms
- CRISPR-Associated Protein 9, Adult, Cell Separation, Female, Humans, Male, T-Lymphocytes, Adaptive Immunity, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
